Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | CHIEF FINANCIAL OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2036-09-15 | Direct | 118,476 |
Reported balance
After 2026-09-15 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-09-15 · Grant · Acquired 118,476 · Balance 118,476 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 118,476 |
Reported balance
After 2026-09-15 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2026-09-15 · Grant · Acquired 118,476 · Balance 118,476 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock. F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.
F3: The original Form 4 filed by the Reporting Person erroneously reflected an incorrect vesting schedule. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through the applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean September 15, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 165,108 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2027-05-18 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 67,164 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 68,460 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 44,184 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 8,136 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 10,404 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-05 · Disposition to issuer · Disposed 83,844 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-05 · Disposition to issuer · Disposed 12,576 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-05 · Disposition to issuer · Disposed 144,828 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-05 · Disposition to issuer · Disposed 86,928 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-05 · Disposition to issuer · Disposed 43,824 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-05-05 · Disposition to issuer · Disposed 70,092 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.
F5: These stock options were granted with automatic vesting on exercisable date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2020 Filed Jun 8, 2020 20:04 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 86,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015697 · doc4.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,928 Underlying: Ordinary Shares · 86,928 shares Expires not disclosed F2 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:04 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantShare Options · Derivative | 144,828 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015697 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,828 Underlying: Ordinary Shares · 144,828 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 8,136 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013766 · doc4.xml · derivative · entry 6 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,136 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 108,468 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013766 · doc4.xml · derivative · entry 5 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 108,468 shares Expires 2020-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 4,032 | $9.67 | $38,989.44 |
DisclosureSEC source: 0000899243-20-013766 · doc4.xml · nonDerivative · entry 4 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,062 F3 · shares: Represented by ADS. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 8,136 | $0.00 | $9.76 |
DisclosureSEC source: 0000899243-20-013766 · doc4.xml · nonDerivative · entry 3 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Tax withholdingOrdinary Shares | 53,784 | $9.67 | $520,091.28 |
DisclosureSEC source: 0000899243-20-013766 · doc4.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,958 F3 · shares: Represented by ADS. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 18, 2020 Filed May 20, 2020 20:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 108,468 | $0.00 | $130.16 |
DisclosureSEC source: 0000899243-20-013766 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.22 U.S. Dollars as of May 18, 2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 18:07 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | PurchaseOrdinary Shares | 7,200 | $6.80 | $48,960.00 |
DisclosureSEC source: 0000899243-20-008656 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,224 F1 · kind: Open market purchase. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 18:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 2,220 | $8.34 | $18,514.80 |
DisclosureSEC source: 0000899243-20-006992 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,024 F1 · kind: Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 228 | $9.17 | $2,090.76 |
DisclosureSEC source: 0000899243-20-006327 · doc4.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,244 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 18:01 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 3,624 | $9.17 | $33,232.08 |
DisclosureSEC source: 0000899243-20-006327 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,472 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| May 20, 2019 Filed May 21, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 4,224 | $14.52 | $61,332.48 |
DisclosureSEC source: 0000899243-19-014293 · doc4.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,096 F4 · shares: Represented by ADSs. F5 · price: The price reported in Column 4 is price per ordinary share converted from price per ADS. Read SEC document |
| May 18, 2019 Filed May 21, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionRestricted Stock Units · Derivative | 8,136 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014293 · doc4.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,136 shares Expires 2019-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 17, 2019. F6 · derivative.expiration_date: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 8,136 ordinary shares vesting on May 18, 2019 and expiring on March 15, 2020. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. Read SEC document |
| May 18, 2019 Filed May 21, 2019 20:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 8,136 | $0.00 | $10.58 |
DisclosureSEC source: 0000899243-19-014293 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.27 U.S. Dollars as of May 17, 2019. F3 · balance_after: Includes 47,496 and 25,152 ordinary shares underlying restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018 and Form 4 filed on March 5, 2019, respectively. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 6,288 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006326 · doc4.xml · derivative · entry 6 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 Underlying: Ordinary Shares · 6,288 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 6,288 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006326 · doc4.xml · derivative · entry 5 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 Underlying: Ordinary Shares · 6,288 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 6,288 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006326 · doc4.xml · derivative · entry 4 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 Underlying: Ordinary Shares · 6,288 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 6,288 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006326 · doc4.xml · derivative · entry 3 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,288 Underlying: Ordinary Shares · 6,288 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 83,844 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006326 · doc4.xml · derivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,844 Underlying: Ordinary Shares · 83,844 shares Expires 2023-03-15 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:03 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 44,184 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0000899243-19-006326 · doc4.xml · derivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,184 Underlying: Ordinary Shares · 44,184 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · security: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 17:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 10,404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005257 · doc4.xml · derivative · entry 5 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3 Underlying: Ordinary Shares · 10,404 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 17:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 48 | $12.38 | $594.24 |
DisclosureSEC source: 0000899243-19-005257 · doc4.xml · nonDerivative · entry 4 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,536 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 17:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 3,600 | $12.46 | $44,856.00 |
DisclosureSEC source: 0000899243-19-005257 · doc4.xml · nonDerivative · entry 3 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,584 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 17:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 1,584 | $12.42 | $19,673.28 |
DisclosureSEC source: 0000899243-19-005257 · doc4.xml · nonDerivative · entry 2 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,184 F3 · shares: These ordinary shares are represented by ADSs. F4 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 17:00 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 10,404 | $0.00 | $13.53 |
DisclosureSEC source: 0000899243-19-005257 · doc4.xml · nonDerivative · entry 1 Giacobello Scott M. · CIK 0001754154 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into 867 American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.29 U.S. Dollars as of February 26, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.